EPHA2
Reaktivität: Human
ELISA, IHC, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western Bloting: 1/500 - 1/2000. Immunohistochemistry: 1/200 - 1/1000. ELISA: Propose dilution 1/10000. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Landen, Kinch, Sood: "EphA2 as a target for ovarian cancer therapy." in: Expert opinion on therapeutic targets, Vol. 9, Issue 6, pp. 1179-87, (2005) (PubMed).
EPH receptor A2 (EphA2), with 976-amino acid protein (about 107 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4 and EphB6 are Eph family receptors for Ephrin family ligands. In normal cells, EphA2 negatively regulates cell growth and invasiveness. EphA2 is overexpressed by many human cancers, and is often associated with poor prognostic features. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.EphA2 may serve as a novel target for bladder cancer, colonic adenocarcinoma and ovarian cancer therapy. Synonyms: ECK, EPHA2